Clinical Trials Logo

Open-Angle Glaucoma clinical trials

View clinical trials related to Open-Angle Glaucoma.

Filter by:

NCT ID: NCT01312454 Terminated - Ocular Hypertension Clinical Trials

Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the safety and efficacy of AL-59412C injected intravitreally relative to Vehicle.

NCT ID: NCT00961649 Terminated - Ocular Hypertension Clinical Trials

Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study was to compare the safety and intraocular pressure (IOP)-lowering efficacy of a new fixed combination of brinzolamide/brimonidine (Brinz/Brim) to: - its individual components (Brinz and Brim), and - the concomitant administration of Brinz and Brim (Brinz+Brim).

NCT ID: NCT00912054 Terminated - Ocular Hypertension Clinical Trials

DuoTrav APS Versus XALACOM® in Ocular Surface Health

Start date: March 2010
Phase: Phase 3
Study type: Interventional

To demonstrate superiority of DuoTrav APS over XALACOM® in Ocular Surface Health in patients with open angle glaucoma or ocular hypertension.

NCT ID: NCT00901108 Terminated - Open Angle Glaucoma Clinical Trials

Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma

Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of Trabectome versus Trabeculectomy with adjunctive Mitomycin C, combined with cataract surgery, in patients with open angle glaucoma.

NCT ID: NCT00804323 Terminated - Open-Angle Glaucoma Clinical Trials

PASCAL Trabeculoplasty

Start date: December 2007
Phase: N/A
Study type: Interventional

Argon laser trabeculoplasty (ALT) with 100 ms pulses is an effective therapy for lowering intraocular pressure (IOP). Similar reductions in IOP have been achieved using ns (SLT) and microsecond (MLT) pulses, which produce less thermal damage to trabecular meshwork (TM). Lack of clinically visible changes may make the accurate alignment of subsequent pulses difficult. We describe a novel technique - Patterned Laser Trabeculoplasty (PLT) using the PASCAL Photocoagulator system, and its preliminary evaluation in patients with open angle glaucoma.

NCT ID: NCT00788541 Terminated - Ocular Hypertension Clinical Trials

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT00471068 Terminated - Ocular Hypertension Clinical Trials

Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension

Start date: March 2007
Phase: Phase 4
Study type: Interventional

To compare the efficacy and safety in patients treated with travoprost versus dorzolamide/timolol maleate combination in patients with open-angle glaucoma or ocular hypertension

NCT ID: NCT00047606 Terminated - Ocular Hypertension Clinical Trials

Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32

Start date: August 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate safety and efficacy of two different IOP lowering medications after six weeks of treatment in Caucasian and Japanese subjects.

NCT ID: NCT00047554 Terminated - Ocular Hypertension Clinical Trials

Study of TRAVATAN in Subjects With Iris Pigmentation Changes

Start date: May 2003
Phase: Phase 4
Study type: Observational

The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension. To be eligible for the study, these individuals must have experienced an iris pigmentation change while previously dosing with TRAVATAN.